company background image
AKP logo

Anika Therapeutics DB:AKP Stock Report

Last Price

€23.40

Market Cap

€344.4m

7D

0.9%

1Y

-10.0%

Updated

25 Mar, 2024

Data

Company Financials +

AKP Stock Overview

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.

AKP fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for AKP from our risk checks.

Anika Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anika Therapeutics
Historical stock prices
Current Share PriceUS$23.40
52 Week HighUS$26.40
52 Week LowUS$15.80
Beta0.75
1 Month Change2.63%
3 Month Change14.71%
1 Year Change-10.00%
3 Year Change-26.88%
5 Year Change-13.14%
Change since IPO383.03%

Recent News & Updates

Recent updates

Shareholder Returns

AKPDE BiotechsDE Market
7D0.9%3.3%1.6%
1Y-10.0%35.8%6.4%

Return vs Industry: AKP underperformed the German Biotechs industry which returned 35.3% over the past year.

Return vs Market: AKP underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is AKP's price volatile compared to industry and market?
AKP volatility
AKP Average Weekly Movement4.5%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: AKP has not had significant price volatility in the past 3 months.

Volatility Over Time: AKP's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1983357Cheryl Blanchardhttps://www.anika.com

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief.

Anika Therapeutics, Inc. Fundamentals Summary

How do Anika Therapeutics's earnings and revenue compare to its market cap?
AKP fundamental statistics
Market cap€344.40m
Earnings (TTM)-€76.27m
Revenue (TTM)€153.76m

2.2x

P/S Ratio

-4.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AKP income statement (TTM)
RevenueUS$166.66m
Cost of RevenueUS$62.83m
Gross ProfitUS$103.84m
Other ExpensesUS$186.50m
Earnings-US$82.67m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.64
Gross Margin62.30%
Net Profit Margin-49.60%
Debt/Equity Ratio0%

How did AKP perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.